# Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Source: https://onco.cc/trials/nct02872103/  
OnCo record `nct02872103` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Efbemalenograstim alfa in Breast cancer, run by EVIVE Biotechnology, completed.

## Summary

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy is a phase 3 interventional study registered as NCT02872103 by EVIVE Biotechnology, with 122 participants recorded, started 2016-08 and reaching its primary completion in 2017-12-20. Interventions recorded: F-627, Placebo. Conditions recorded: Breast Cancer, Neutropenia.

Linked to the drug Efbemalenograstim alfa because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02872103
- Phase: 3
- Setting: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
- Sponsor: EVIVE Biotechnology
- Enrolled: 122

## Sources

- ClinicalTrials.gov NCT02872103: https://clinicaltrials.gov/study/NCT02872103

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Efbemalenograstim alfa](https://onco.cc/drugs/efbemalenograstim-alfa/)
- companies: [Evive Biotech](https://onco.cc/companies/evive-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct02872103.json